- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05817175
International Prospective REgistry on Pre-pectorAl Breast REconstruction (I-PREPARE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Rosa Di Micco, Dr
- Phone Number: 4565 +390226431
- Email: dimicco.rosa@hsr.it
Study Contact Backup
- Name: Oreste D Gentilini, Dr
- Phone Number: 3939 +390226431
- Email: gentilini@eubreast.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
All patients who are candidates for implant-based reconstruction should be informed about the possible participation to this clinical study. The inclusion and exclusion criteria are verified by the investigator and an informed consent is obtained from the patient.
The therapeutic pattern should be followed according to institutional and national standards. Since this is a non-interventional trial, the study sites do not deviate from their own study protocol at any timepoint.
Description
Inclusion Criteria:
- Female patients older than 18 years old
- Signed informed consent form
- Patients undergoing mono or bilateral therapeutic mastectomy
- Patients undergoing pre-pectoral implant-based breast reconstruction with implant or expander with or without mesh
Exclusion Criteria:
- Male patients
- Patients not suitable for surgical treatment
- Patients undergoing subpectoral reconstruction
- Patients undergoing breast reconstruction with autologous tissue.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with Implant-loss at three months postoperatively
Time Frame: three months postoperatively
|
Rate of implant-loss at three months postoperatively defined as the unplanned removal or loss of the implant as a result of infection or other complication
|
three months postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with Infection
Time Frame: three months postoperatively
|
Rate of infection defined as minor if oral antibiotic was required, major if surgical revision and/or hospitalisation was necessary;
|
three months postoperatively
|
Number of patients with re-admission and re-operation
Time Frame: three months postoperatively
|
Rate of re-admission and re-operation
|
three months postoperatively
|
Evaluation of Quality of life
Time Frame: 0, 6, 12 and 24 months
|
Patient's satisfaction and quaity of life measured through BREASTQ (Breast Reconstruction Module Questionnaire)
|
0, 6, 12 and 24 months
|
Number of Early onset complication
Time Frame: three months postoperatively
|
Early onset complication at 3 month follow up: seroma, hematoma/bleeding, skin flap or T junction necrosis, nipple necrosis, wound dehiscence, implant malposition (i.e.
rotation, displacement etc..), red-breast syndrome
|
three months postoperatively
|
Number of late-onset complications
Time Frame: 6-12-24 months
|
seroma, capsular contracture, wrinkling/rippling, implant malposition (i.e.
rotation, displacement etc..) implant upper pole visibility, implant loss;
|
6-12-24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Oreste D Gentilini, Dr, IRCCS San Raffaele
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EUBREAST-11R
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
Clinical Trials on pre-pectoral breast reconstruction
-
The Leeds Teaching Hospitals NHS TrustRecruitingBreast Cancer | Surgery | Patient Satisfaction | Breast DiseaseUnited Kingdom
-
Tianjin Medical University Cancer Institute and...RecruitingBreast Cancer | Breast Reconstruction | Radiation | Synthetic MeshUnited States, China, Germany
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationActive, not recruitingBreast Reconstruction | Implant-Based Breast Reconstruction (IBBR)Austria, Sweden, Germany, Hungary, Switzerland, United States, Italy
-
Tela Bio IncMCRARecruitingReconstructive Surgical ProceduresUnited States
-
Johns Hopkins UniversityCompletedQuality of Life | Breast Cancer | Postoperative Pain | Postoperative Nausea and Vomiting | Breast Prosthesis; PainUnited States
-
Guy's and St Thomas' NHS Foundation TrustUnknown
-
The Netherlands Cancer InstituteMaastricht University Medical Center; Erasmus Medical Center; Ziekenhuisgroep... and other collaboratorsEnrolling by invitationAutoimmune Diseases | Breast Cancer | Breast Implant; ComplicationsNetherlands
-
Case Comprehensive Cancer CenterWithdrawnBreast Cancer | Malignant Neoplasm of BreastUnited States
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
Case Comprehensive Cancer CenterWithdrawnBreast Reconstruction | MastectomyUnited States